Viral vectors, animal models and new therapies for Parkinson's disease
- PMID: 18585946
- DOI: 10.1016/j.parkreldis.2008.04.024
Viral vectors, animal models and new therapies for Parkinson's disease
Abstract
The involvement of alpha-synuclein in familial forms of Parkinson's disease suggests a potential causative role in the pathogenesis. We have explored the possibility of generating animal models of Parkinson's disease by overexpressing alpha-synuclein in the nigrostriatal pathway using viral vectors. Both lentiviral and adeno-associated vectors efficiently transduce dopaminergic neurons in the substantia nigra, and transgenic expression of alpha-synuclein leads to the progressive loss of neurons positive for dopaminergic markers, with the formation of intraneuronal alpha-synuclein aggregates. With a high tropism for nigral dopaminergic neurons, adeno-associated vectors allow for the monitoring of dopaminergic function using spontaneous and drug-induced behaviour. We propose that virus-based rodent alpha-synuclein models provide a valuable approach for the preclinical testing of therapeutics.
Similar articles
-
Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.J Neurochem. 2004 Oct;91(2):451-61. doi: 10.1111/j.1471-4159.2004.02728.x. J Neurochem. 2004. PMID: 15447678
-
alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10813-8. doi: 10.1073/pnas.152339799. Epub 2002 Jul 16. Proc Natl Acad Sci U S A. 2002. PMID: 12122208 Free PMC article.
-
Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease.Neurobiol Dis. 2004 Nov;17(2):283-9. doi: 10.1016/j.nbd.2004.06.008. Neurobiol Dis. 2004. PMID: 15474365
-
Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease.Prog Brain Res. 2010;184:89-111. doi: 10.1016/S0079-6123(10)84005-1. Prog Brain Res. 2010. PMID: 20887871 Review.
-
In vivo gene delivery for development of mammalian models for Parkinson's disease.Exp Neurol. 2008 Jan;209(1):89-100. doi: 10.1016/j.expneurol.2007.09.011. Epub 2007 Sep 22. Exp Neurol. 2008. PMID: 18028909 Review.
Cited by
-
Parkinson's disease: insights from pathways.Hum Mol Genet. 2010 Apr 15;19(R1):R21-7. doi: 10.1093/hmg/ddq167. Epub 2010 Apr 26. Hum Mol Genet. 2010. PMID: 20421364 Free PMC article. Review.
-
Optimized quantities of GDNF overexpressed by engineered astrocytes are critical for protection of neuroblastoma cells against 6-OHDA toxicity.J Mol Neurosci. 2012 Mar;46(3):654-65. doi: 10.1007/s12031-011-9654-8. Epub 2011 Oct 4. J Mol Neurosci. 2012. PMID: 21969113
-
Differential Cellular Tropism of Lentivirus and Adeno-Associated Virus in the Brain of Cynomolgus Monkey.Exp Neurobiol. 2016 Feb;25(1):48-54. doi: 10.5607/en.2016.25.1.48. Epub 2016 Feb 22. Exp Neurobiol. 2016. PMID: 26924933 Free PMC article.
-
Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.Neurotox Res. 2009 Aug;16(2):127-39. doi: 10.1007/s12640-009-9061-x. Epub 2009 May 27. Neurotox Res. 2009. PMID: 19526289
-
Proteostasis and movement disorders: Parkinson's disease and amyotrophic lateral sclerosis.Cold Spring Harb Perspect Biol. 2011 Oct 1;3(10):a007500. doi: 10.1101/cshperspect.a007500. Cold Spring Harb Perspect Biol. 2011. PMID: 21844169 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical